-
1
-
-
0028970456
-
Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
-
Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45-59, 1995 (Pubitemid 24370135)
-
(1995)
Seminars in Hematology
, vol.32
, Issue.1
, pp. 45-59
-
-
Kyle, R.A.1
Gertz, M.A.2
-
2
-
-
78851472260
-
Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
-
Gertz MA: Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:180-186, 2011
-
(2011)
Am J Hematol
, vol.86
, pp. 180-186
-
-
Gertz, M.A.1
-
3
-
-
0022495898
-
Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases
-
Kyle RA, Greipp PR, O'Fallon WM: Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 68:220-224, 1986 (Pubitemid 16033633)
-
(1986)
Blood
, vol.68
, Issue.1
, pp. 220-224
-
-
Kyle, R.A.1
Greipp, P.R.2
O'Fallon, W.M.3
-
4
-
-
0036853299
-
Stem cell transplantation for the management of primary systemic amyloidosis
-
DOI 10.1016/S0002-9343(02)01208-1, PII S0002934302012081
-
Gertz MA, Lacy MQ, Dispenzieri A, et al: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113:549-555, 2002 (Pubitemid 35379909)
-
(2002)
American Journal of Medicine
, vol.113
, Issue.7
, pp. 549-555
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
Gastineau, D.A.4
Chen, M.G.5
Ansell, S.M.6
Inwards, D.J.7
Micallef, I.N.M.8
Tefferi, A.9
Litzow, M.R.10
-
5
-
-
33846828703
-
Transplantation for amyloidosis
-
DOI 10.1097/CCO.0b013e32801494c6, PII 0000162220070300000012
-
Gertz MA, Lacy MQ, Dispenzieri A, et al: Transplantation for amyloidosis. Curr Opin Oncol 19:136-141, 2007 (Pubitemid 46204353)
-
(2007)
Current Opinion in Oncology
, vol.19
, Issue.2
, pp. 136-141
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
Hayman, S.R.4
Kumar, S.5
-
6
-
-
0034747773
-
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
-
DOI 10.1038/sj.bmt.1703200
-
Sanchorawala V, Wright DG, Seldin DC, et al: An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28:637-642, 2001 (Pubitemid 33014596)
-
(2001)
Bone Marrow Transplantation
, vol.28
, Issue.7
, pp. 637-642
-
-
Sanchorawala, V.1
Wright, D.G.2
Seldin, D.C.3
Dember, L.M.4
Finn, K.5
Falk, R.H.6
Berk, J.7
Quillen, K.8
Skinner, M.9
-
7
-
-
38049059363
-
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
-
author reply 92-93
-
Kumar S, Dispenzieri A, Gertz MA: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 358:91, 2008; author reply 92-93
-
(2008)
N Engl J Med
, vol.358
, pp. 91
-
-
Kumar, S.1
Dispenzieri, A.2
Gertz, M.A.3
-
8
-
-
11144358046
-
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
-
DOI 10.1182/blood-2003-08-2788
-
Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938, 2004 (Pubitemid 38451663)
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 2936-2938
-
-
Palladini, G.1
Perfetti, V.2
Obici, L.3
Caccialanza, R.4
Semino, A.5
Adami, F.6
Cavallero, G.7
Rustichelli, R.8
Virga, G.9
Merlini, G.10
-
9
-
-
33846263334
-
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
-
DOI 10.1182/blood-2006-07-035352
-
Wechalekar AD, Goodman HJ, Lachmann HJ, et al: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457-464, 2007 (Pubitemid 46105938)
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 457-464
-
-
Wechalekar, A.D.1
Goodman, H.J.B.2
Lachmann, H.J.3
Offer, M.4
Hawkins, P.N.5
Gillmore, J.D.6
-
10
-
-
33846258025
-
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
-
DOI 10.1182/blood-2006-07-032987
-
Dispenzieri A, Lacy MQ, Zeldenrust SR, et al: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470, 2007 (Pubitemid 46105939)
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 465-470
-
-
Dispenzieri, A.1
Lacy, M.Q.2
Zeldenrust, S.R.3
Hayman, S.R.4
Kumar, S.K.5
Geyer, S.M.6
Lust, J.A.7
Allred, J.B.8
Witzig, T.E.9
Rajkumar, S.V.10
Greipp, P.R.11
Russell, S.J.12
Kabat, B.13
Gertz, M.A.14
-
11
-
-
77949897868
-
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis
-
Kastritis E, Wechalekar AD, Dimopoulos MA, et al: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28:1031-1037, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 1031-1037
-
-
Kastritis, E.1
Wechalekar, A.D.2
Dimopoulos, M.A.3
-
12
-
-
4644336052
-
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
-
DOI 10.1200/JCO.2004.03.029
-
Dispenzieri A, Gertz MA, Kyle RA, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004 (Pubitemid 41095215)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.18
, pp. 3751-3757
-
-
Dispenzieri, A.1
Gertz, M.A.2
Kyle, R.A.3
Lacy, M.Q.4
Burritt, M.F.5
Therneau, T.M.6
Greipp, P.R.7
Witzig, T.E.8
Lust, J.A.9
Rajkumar, S.V.10
Fonseca, R.11
Zeldenrust, S.R.12
McGregor, C.G.A.13
Jaffe, A.S.14
-
13
-
-
4444268210
-
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
-
DOI 10.1182/blood-2004-01-0390
-
Dispenzieri A, Gertz MA, Kyle RA, et al: Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104: 1881-1887, 2004 (Pubitemid 39202301)
-
(2004)
Blood
, vol.104
, Issue.6
, pp. 1881-1887
-
-
Dispenzieri, A.1
Gertz, M.A.2
Kyle, R.A.3
Lacy, M.Q.4
Burritt, M.F.5
Therneau, T.M.6
McConnell, J.P.7
Litzow, M.R.8
Gastineau, D.A.9
Tefferi, A.10
Inwards, D.J.11
Micallef, I.N.12
Ansell, S.M.13
Porrata, L.F.14
Elliott, M.A.15
Hogan, W.J.16
Rajkumar, S.V.17
Fonseca, R.18
Greipp, P.R.19
Witzig, T.E.20
Lust, J.A.21
Zeldenrust, S.R.22
Snow, D.S.23
Hayman, S.R.24
McGregor, C.G.A.25
Jaffe, A.S.26
more..
-
14
-
-
0038778403
-
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
-
DOI 10.1016/S0140-6736(03)13396-X
-
Dispenzieri A, Kyle RA, Gertz MA, et al: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787-1789, 2003 (Pubitemid 36638428)
-
(2003)
Lancet
, vol.361
, Issue.9371
, pp. 1787-1789
-
-
Dispenzieri, A.1
Kyle, R.A.2
Gertz, M.A.3
Therneau, T.M.4
Miller, W.L.5
Chandrasekaran, K.6
McConnell, J.P.7
Burritt, M.F.8
Jaffe, A.S.9
-
15
-
-
0038518441
-
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
-
DOI 10.1161/01.CIR.0000068314.02595.B2
-
Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003 (Pubitemid 36605226)
-
(2003)
Circulation
, vol.107
, Issue.19
, pp. 2440-2445
-
-
Palladini, G.1
Campana, C.2
Klersy, C.3
Balduini, A.4
Vadacca, G.5
Perfetti, V.6
Perlini, S.7
Obici, L.8
Ascari, E.9
D'Eril, G.M.10
Moratti, R.11
Merlini, G.12
-
16
-
-
5644268954
-
N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients
-
DOI 10.1161/01.CIR.0000144310.04433.BE
-
Bettencourt P, Azevedo A, Pimenta J, et al: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110:2168-2174, 2004 (Pubitemid 39372496)
-
(2004)
Circulation
, vol.110
, Issue.15
, pp. 2168-2174
-
-
Bettencourt, P.1
Azevedo, A.2
Pimenta, J.3
Frioes, F.4
Ferreira, S.5
Ferreira, A.6
-
17
-
-
78650037877
-
Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features
-
Kumar S, Dispenzieri A, Katzmann JA, et al: Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 116:5126-5129, 2010
-
(2010)
Blood
, vol.116
, pp. 5126-5129
-
-
Kumar, S.1
Dispenzieri, A.2
Katzmann, J.A.3
-
18
-
-
36349007621
-
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response
-
DOI 10.3324/haematol.11413
-
Gertz MA, Lacy MQ, Dispenzieri A, et al: Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 92:1415-1418, 2007 (Pubitemid 350144161)
-
(2007)
Haematologica
, vol.92
, Issue.10
, pp. 1415-1418
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
Hayman, S.R.4
Kumar, S.K.5
Leung, N.6
Gastineau, D.A.7
-
19
-
-
78650073315
-
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report
-
Gertz MA, Lacy MQ, Dispenzieri A, et al: Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report. Leuk Lymphoma 51:2181-2187, 2010
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 2181-2187
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
-
20
-
-
1642421878
-
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
-
Dispenzieri A, Lacy MQ, Rajkumar SV, et al: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10:257-261, 2003 (Pubitemid 38117510)
-
(2003)
Amyloid
, vol.10
, Issue.4
, pp. 257-261
-
-
Dispenzieri, A.1
Lacy, M.Q.2
Rajkumar, S.V.3
Geyer, S.M.4
Witzig, T.E.5
Fonseca, R.6
Lust, J.A.7
Greipp, P.R.8
Kyle, R.A.9
Gertz, M.A.10
-
21
-
-
17744370515
-
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice
-
DOI 10.1373/clinchem.2004.046870
-
Katzmann JA, Abraham RS, Dispenzieri A, et al: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51:878-881, 2005 (Pubitemid 40577925)
-
(2005)
Clinical Chemistry
, vol.51
, Issue.5
, pp. 878-881
-
-
Katzmann, J.A.1
Abraham, R.S.2
Dispenzieri, A.3
Lust, J.A.4
Kyle, R.A.5
-
22
-
-
78649497426
-
Immunophenotyping in multiple myeloma and related plasma cell disorders
-
Kumar S, Kimlinger T, Morice W: Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 23:433-451, 2010
-
(2010)
Best Pract Res Clin Haematol
, vol.23
, pp. 433-451
-
-
Kumar, S.1
Kimlinger, T.2
Morice, W.3
-
24
-
-
0037305628
-
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
-
DOI 10.1182/blood-2002-06-1698
-
Pardanani A, Witzig TE, Schroeder G, et al: Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 101:827-830, 2003 (Pubitemid 36139346)
-
(2003)
Blood
, vol.101
, Issue.3
, pp. 827-830
-
-
Pardanani, A.1
Witzig, T.E.2
Schroeder, G.3
McElroy, E.A.4
Fonseca, R.5
Dispenzieri, A.6
Lacy, M.O.7
Lust, J.A.8
Kyle, R.A.9
Greipp, P.R.10
Gertz, M.A.11
Rajkumar, S.V.12
-
25
-
-
79955842001
-
Amyloidosis: Pathogenesis and new therapeutic options
-
Merlini G, Seldin DC, Gertz MA: Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 29:1924-1933, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 1924-1933
-
-
Merlini, G.1
Seldin, D.C.2
Gertz, M.A.3
-
26
-
-
78650987230
-
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
-
Kumar SK, Gertz MA, Lacy MQ, et al: Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86:12-18, 2011
-
(2011)
Mayo Clin Proc
, vol.86
, pp. 12-18
-
-
Kumar, S.K.1
Gertz, M.A.2
Lacy, M.Q.3
-
27
-
-
79951934818
-
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
-
Kumar SK, Dispenzieri A, Lacy MQ, et al: Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86:251-255, 2011
-
(2011)
Am J Hematol
, vol.86
, pp. 251-255
-
-
Kumar, S.K.1
Dispenzieri, A.2
Lacy, M.Q.3
-
28
-
-
30944433400
-
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
-
DOI 10.1038/sj.bmt.1705106, PII 1705106
-
Sanchorawala V, Seldin DC, Magnani B, et al: Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36:597-600, 2005 (Pubitemid 43115014)
-
(2005)
Bone Marrow Transplantation
, vol.36
, Issue.7
, pp. 597-600
-
-
Sanchorawala, V.1
Seldin, D.C.2
Magnani, B.3
Skinner, M.4
Wright, D.G.5
-
29
-
-
0024400268
-
The plasma cell labeling index: A valuable tool in primary systemic amyloidosis
-
Gertz MA, Kyle RA, Greipp PR: The plasma cell labeling index: A valuable tool in primary systemic amyloidosis. Blood 74:1108-1111, 1989 (Pubitemid 19210031)
-
(1989)
Blood
, vol.74
, Issue.3
, pp. 1108-1111
-
-
Gertz, M.A.1
Kyle, R.A.2
Greipp, P.R.3
-
30
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 3412-3420
-
-
Greipp, P.R.1
San Miguel, J.2
Durie, B.G.3
|